Quantifying Hepatic Mitochondrial Fluxes in Humans
NCT05305287
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Non-Alcoholic Fatty Liver Disease
- Type 2 Diabetes
- Mitochondrial Metabolism Disorders
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- The University of Texas Health Science Center at San Antonio
- Last updated on ClinicalTrials.gov
- August 17, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Texas · 2
- Texas Diabetes Institute - University Health System · San Antonio, TX
- University of Texas Health Science Center at San Antonio · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.